Topics
October 2016 | Cover Focus: New Developments
5-Year Results With a Retinal Prosthesis System
Patients with severe to profound RP are experiencing promising outcomes with the Argus II.
Lyndon da Cruz, MA, MD, PhD
September 11, 2026
Galimedix Therapeutics to Present Functional Feasibility Data from Phase 2 eDREAM study in GA at Euretina
September 10, 2026
Researchers Develop an AI System to Predict the Need for Therapy in Intermediate AMD
September 9, 2026
Johnson & Johnson Appoints Jacqueline Henderson Company Group Chair, Vision
FDA Accepts Nanoscope’s BLA for Optogenetic Gene Therapy Mogenry in Retinitis Pigmentosa
September 2026 Insert
Editorially Independent Content, Supported With Advertising From Astellas
Editorially independent supported by Abbvie and Regenxbio
September 2026 Supplement
Editorially independent content supported with advertising by Eyepoint
Free Print Subscription
Email Newsletter
Conference Calendar
